CMC Biologics.

CMC Biologics, Route Malaria Vaccine Initiative signal agreement for development of specific monoclonal antibodies CMC Biologics, a worldwide leader in clinical and industrial contract and development manufacture of therapeutic proteins, announced today it has entered into an agreement with the PATH Malaria Vaccine Initiative for process advancement and manufacture of specific monoclonal antibodies to check for their capacity to safeguard human beings from malaria infection .